^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LAE001
i
Other names: LAE001, CFG920, CFG-920, LAE 001, LAE-001, CFG 920
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Laekna Therap, Novartis
Drug class:
CYP17A1 inhibitor, Aldosterone synthase inhibitor
Related drugs:
3ms
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
P1/2, N=49, Completed, Laekna Limited | Active, not recruiting --> Completed | N=74 --> 49 | Trial completion date: Oct 2024 --> Mar 2024
Trial completion • Enrollment change • Trial completion date • Metastases
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • BRCA (Breast cancer early onset)
|
docetaxel • prednisone • afuresertib (LAE002) • LAE001
9ms
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer (clinicaltrials.gov)
P1/2, N=33, Suspended, Laekna Limited | N=80 --> 33 | Trial completion date: Aug 2022 --> Jun 2025 | Unknown status --> Suspended | Trial primary completion date: Feb 2022 --> Oct 2023
Enrollment change • Trial completion date • Trial suspension • Trial primary completion date
|
LAE001
over1year
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
P1/2, N=74, Active, not recruiting, Laekna Limited | Recruiting --> Active, not recruiting
Enrollment closed
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
docetaxel • prednisone • afuresertib (LAE002) • LAE001
almost2years
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
P1/2, N=74, Recruiting, Laekna Limited | Trial completion date: Oct 2022 --> Oct 2024 | Trial primary completion date: Sep 2022 --> Oct 2023
Trial completion date • Trial primary completion date • Metastases
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
docetaxel • prednisone • afuresertib (LAE002) • LAE001
almost3years
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC (clinicaltrials.gov)
P1/2, N=74, Recruiting, Laekna Limited | Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
Clinical • Trial completion date • Trial primary completion date
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog)
|
docetaxel • prednisone • afuresertib (LAE002) • LAE001
Share via
